ESC 365 - The impact of the WCD for patients who choose to wear it.

EHRA Premium Access

The impact of the WCD for patients who choose to wear it.

Session: Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death

Topic: ARRHYTHMIAS AND DEVICE THERAPY

Speaker: Professor D. Scherr (Graz, AT)

Sponsored by ZOLL

Event: EHRA 2019

Congress Presentation

Add to my library

About the speaker

Professor Daniel Scherr

Medical University of Graz, Graz (Austria)

19 presentations

3 followers

4 more presentations in this session

Introduction - Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death.

Speaker: Doctor G. Botto (Garbagnate Milanese, IT)

Distilling the clinical evidence behind the WCD - What have clinical trials and registries told us?

Speaker: Doctor S. Reif (Munich, DE)

Strategies for screening and identifying which patients to protect with the WCD.

Speaker: Professor J. Ehrlich (Wiesbaden, DE)

Panel discussion and summary - Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death.

Speaker: Doctor O. Piot (Saint Denis, FR)

Access the full session

Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death

Speakers: Professor D. Scherr, Doctor G. Botto, Doctor S. Reif, Professor J. Ehrlich, Doctor O. Piot

About the event

EHRA 2019

17 March - 19 March 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources